GlobeNewswire: Qualigen Therapeutics, Inc. Contains the last 10 of 129 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:03:55ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/11/14/2780571/0/en/Qualigen-Therapeutics-Provides-Corporate-Update-for-Third-Quarter-and-To-Date-2023.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 20232023-11-14T21:30:00Z<![CDATA[CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today provides a corporate update for the third quarter ending September 30, 2023 and to date:]]>https://www.globenewswire.com/news-release/2023/11/07/2775116/0/en/Qualigen-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1a-Clinical-Trial-of-QN-302-for-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors2023-11-07T13:30:00Z<![CDATA[CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan.]]>https://www.globenewswire.com/news-release/2023/10/23/2764724/0/en/Poster-Highlighting-Qualigen-Therapeutics-Pan-RAS-Inhibitor-Platform-Presented-at-AACR-Special-Conference-Advances-in-Breast-Cancer.html?f=22&fvtc=4&fvtv=28400Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer2023-10-23T12:30:00Z<![CDATA[Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models]]>https://www.globenewswire.com/news-release/2023/09/27/2750380/0/en/Qualigen-Therapeutics-Presents-Scientific-Data-on-QN-302-at-AACR-Special-Conference-Pancreatic-Cancer-2023.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 20232023-09-27T12:30:00Z<![CDATA[Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action]]>Figure 1AQualigen Therapeutics, Inc.Figure 1BQualigen Therapeutics, Inc.Table 1Qualigen Therapeutics, Inc.https://www.globenewswire.com/news-release/2023/08/17/2727243/0/en/Qualigen-Therapeutics-Partners-with-TD2-for-Phase-1-Clinical-Development-of-QN-302-for-the-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors2023-08-17T12:30:00Z<![CDATA[CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.]]>https://www.globenewswire.com/news-release/2023/08/15/2725473/0/en/Qualigen-Therapeutics-Inc-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ending-June-30-2023.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 20232023-08-15T12:30:00Z<![CDATA[Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company]]>https://www.globenewswire.com/news-release/2023/08/01/2715847/0/en/Qualigen-Therapeutics-Announces-US-FDA-IND-Clearance-to-Initiate-Phase-1-Clinical-Trial-of-QN-302-for-Treatment-of-Advanced-or-Metastatic-Solid-Tumors.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors2023-08-01T12:30:00Z<![CDATA[Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology]]>https://www.globenewswire.com/news-release/2023/07/24/2709498/0/en/Qualigen-Therapeutics-Divests-FastPack-Diagnostics-Business.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics Divests FastPack® Diagnostics Business2023-07-24T12:15:00Z<![CDATA[All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics]]>https://www.globenewswire.com/news-release/2023/06/05/2681940/0/en/Poster-Highlighting-Qualigen-Therapeutics-Pan-RAS-Inhibitor-Platform-Presented-at-American-Society-of-Clinical-Oncology-ASCO-2023-Annual-Meeting.html?f=22&fvtc=4&fvtv=28400Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting2023-06-05T12:15:00Z<![CDATA[Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds]]>Co-operation between RAS-F series and AMG-510 and MRTX1133Qualigen Therapeutics, Inc.https://www.globenewswire.com/news-release/2023/05/16/2669913/0/en/Qualigen-Therapeutics-Inc-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ending-March-31-2023.html?f=22&fvtc=4&fvtv=28400Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 20232023-05-16T12:00:00Z<![CDATA[Company Reports 123% Increase in Year-Over-Year Revenue]]>